PRCT PROCEPT BioRobotics Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1588978 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY-35.8%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—
Margins
Gross margin64.7%
Operating margin-33.6%
Net margin-32.6%
FCF margin-24.1%
EBITDA margin-31.3%
Returns
ROE-32.4%
ROA-23.3%
ROIC (approx.)-62.4%
Asset turnover0.72x
Leverage & solvency
Liabilities / assets30.6%
Debt / equity0.16x
Current ratio5.89x
Interest coverage-34.73x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $98.29M | $94.50M | $83.13M | $76.38M | $83.33M | $79.18M | $69.16M | $68.24M |
| Cost of revenue | $33.14M | $32.12M | $29.18M | $30.07M | $29.32M | $27.44M | $25.00M | $24.56M |
| Gross profit | $65.15M | $62.38M | $53.95M | $46.31M | $54.01M | $51.75M | $44.16M | $43.67M |
| R&D expense | $20.01M | $20.10M | $21.46M | $19.06M | $18.19M | $17.63M | $16.40M | $15.07M |
| SG&A expense | $72.51M | $69.67M | $65.09M | $58.30M | $59.01M | $56.30M | $55.20M | $48.32M |
| Operating income | -$27.38M | -$27.39M | -$32.61M | -$31.04M | -$23.19M | -$22.19M | -$27.44M | -$19.71M |
| Interest expense | $856,000 | $842,000 | $818,000 | $894,000 | $919,000 | $895,000 | $877,000 | $969,000 |
| Pretax income | -$26.57M | -$26.77M | -$31.68M | -$29.78M | -$21.38M | -$19.44M | -$24.78M | — |
| Income tax | -$58,000 | $94,000 | -$43,000 | $68,000 | $34,000 | $136,000 | -$47,000 | — |
| Net income | -$26.52M | -$26.86M | -$31.64M | -$29.84M | -$21.41M | -$19.58M | -$24.74M | -$18.86M |
| EBITDA | -$24.84M | -$25.40M | -$30.87M | -$29.33M | -$21.57M | -$20.60M | -$25.96M | -$18.26M |
| EPS (basic) | -0.46 | -0.47 | -0.56 | — | -0.38 | -0.35 | -0.45 | — |
| EPS (diluted) | -0.46 | -0.47 | -0.56 | — | -0.38 | -0.35 | -0.45 | — |
| Weighted avg. shares (diluted) | 57.33M | 57.07M | 56.51M | — | 55.73M | 55.45M | 54.92M | — |
| Banking | ||||||||
| Provision for credit losses | — | — | — | — | — | — | — | $384,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $218.37M | $227.91M | $245.64M | $286.50M | $294.28M | $302.72M | $316.21M | $336.76M |
| Receivables | $105.03M | $107.61M | $96.39M | $83.53M | $84.50M | $80.82M | $79.27M | $83.50M |
| Inventory | $81.41M | $77.06M | $77.54M | $70.69M | $66.72M | $67.03M | $62.33M | $56.17M |
| Current assets | $414.19M | $420.29M | $428.03M | $450.38M | $454.75M | $458.07M | $465.79M | $481.84M |
| PP&E, net | $30.16M | $31.83M | $31.74M | $30.40M | $30.02M | $28.60M | $28.13M | $26.71M |
| Total assets | $473.76M | $479.35M | $487.06M | $508.08M | $511.54M | $513.05M | $519.38M | $534.02M |
| Current liabilities | $70.35M | $64.20M | $63.64M | $65.80M | $53.90M | $49.73M | $52.06M | $53.13M |
| Long-term debt | $51.77M | $51.72M | $51.66M | $51.62M | $51.57M | $51.52M | $51.50M | $51.47M |
| Total debt | $51.77M | $51.72M | $51.66M | $51.62M | $51.57M | $51.52M | $51.50M | $51.47M |
| Total liabilities | $144.85M | $139.28M | $139.40M | $142.21M | $131.26M | $127.26M | $130.22M | $131.80M |
| Shareholders' equity | $328.91M | $340.07M | $347.67M | $365.87M | $380.28M | $385.80M | $389.16M | $402.22M |
| Net debt | -$166.60M | -$176.20M | -$193.98M | -$234.89M | -$242.72M | -$251.19M | -$264.71M | -$285.29M |
| Shares outstanding | 57.44M | 57.25M | 56.90M | 56.32M | 55.87M | 55.58M | 55.28M | 54.72M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.98M | -$19.25M | -$38.13M | -$10.33M | -$6.63M | -$15.04M | -$16.98M | -$32.39M |
| Capital expenditure | $667,000 | $2.95M | $2.91M | $1.85M | $2.87M | $2.80M | $1.84M | $1.17M |
| Free cash flow | -$9.65M | -$22.20M | -$41.04M | -$12.18M | -$9.50M | -$17.84M | -$18.82M | -$33.56M |
| Investing cash flow | -$667,000 | -$2.95M | -$2.91M | -$1.85M | -$2.87M | -$2.80M | -$1.84M | -$1.17M |
| Financing cash flow | $99,000 | $4.50M | $222,000 | $4.44M | $1.08M | $4.38M | $1.30M | $170.53M |
| Depreciation & amortization | $2.54M | $1.99M | $1.74M | $1.71M | $1.62M | $1.59M | $1.48M | $1.45M |
| Stock-based compensation | $15.08M | $14.53M | $13.07M | $10.84M | $14.49M | $12.16M | $10.11M | $9.09M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.